Skip to main content

‘pulmonary hypertension’

BME’s Merryman and collaborators find potential way to prevent rare lung disease

Nov. 20, 2018—Research by Vanderbilt scientists suggests that it may be possible to prevent or even reverse pulmonary arterial hypertension (PAH), a rare, progressive disease characterized by narrowing of and high blood pressure in the small arteries of the lungs. A key player in PAH is the proangiogenic cell (PAC), a cell produced by the bone marrow...

Read more


Merryman wins $6M to address heart disease with arthritis drug, fund other research

Feb. 1, 2017—A Vanderbilt biomedical engineering professor has garnered $6 million total in grants to determine how to treat heart valve disease, pulmonary hypertension and heart failure using drugs originally developed for rheumatoid arthritis and applying the lessons learned from failed weight loss drugs. The larger grant to Associate Professor of Biomedical Engineering David Merryman – the result...

Read more